SCHEMBL4707146

SCHEMBL4707146

ON=C1c2ccccc2Sc2ccccc2C1Cl

nearest known ligand 0.37

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 1/20 0.35
KMT2A Q03164 1/20 0.35
HPGD P15428 3/20 0.33
NPSR1 Q6W5P4 1/20 0.33
GPR84 Q9NQS5 1/20 0.32
CHRM2 P08172 2/20 0.32
HTR1A P08908 2/20 0.32
ADRA2A P08913 2/20 0.32
CYP2D6 P10635 2/20 0.32
CHRM1 P11229 2/20 0.32
DRD1 P21728 2/20 0.32
TBXA2R P21731 2/20 0.32
SLC6A2 P23975 2/20 0.32
SLC6A4 P31645 2/20 0.32
ADRA1A P35348 2/20 0.32
OPRM1 P35372 2/20 0.32
DRD3 P35462 2/20 0.32
KCNH2 Q12809 2/20 0.32
ADORA3 P0DMS8 1/20 0.32
CYP2C19 P33261 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4707143 1.00 MEN1 (0.35) MEN1KMT2AHPGDNPSR1GPR84
SCHEMBL5133396 0.75 MAOA (0.41) MEN1KMT2ACHRM2HTR1AADRA2A
SCHEMBL4708551 0.74 S100A4 (0.42) MEN1KMT2AHPGDCHRM2HTR1A
SCHEMBL11704742 0.63 MAOA (0.34) MEN1KMT2ACHRM2HTR1AADRA2A
SCHEMBL11588872 0.63 ALDH1A1 (0.41) MEN1KMT2AHPGDCHRM2HTR1A
SCHEMBL5266267 0.63 MAOA (0.46) MEN1KMT2ACHRM2HTR1AADRA2A
SCHEMBL904813 0.63 MAOA (0.41) MEN1KMT2ACHRM2HTR1AADRA2A
SCHEMBL10866375 0.63 MAOA (0.31) HPGDALDH1A1
SCHEMBL29697456 0.63 MAOA (0.46) MEN1KMT2ACHRM2HTR1AADRA2A
SCHEMBL19537629 0.61 ALDH1A1 (0.48) MEN1KMT2AHPGDNPSR1GPR84

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1687314-B1 PREPARATION OF 1-AZA-2-OXA-DIBENZO [e,h] AZULENES AND THEIR USE FOR THE MANUFACTURE OF PHARMACEUTICAL FORMULATIONS FOR THE TREATMENT AND PREVENTION OF CENTRAL NERVOUS SYSTEM DISEASES AND DISORDERS GLAXOSMITHKLINE ZAGREB (HR) 2008-12-24 EP disclosed
US-20070078124-A1 1-Aza-2-oxa-dibenzo(e,h)azulenes and their use for the treatment of central nervous system diseases and disorders PLIVA-ISTRAZIVACKI INSTITUT D.O.O. (HR) 2007-04-05 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070078124-A1 1-Aza-2-oxa-dibenzo(e,h)azulenes and their use for the treatment of central nervous system diseases and disorders DBH, AZI2, MAOB MEN1 1279/4885KMT2A 928/4885HPGD 607/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.